← Leaderboards
Samuel V Alworth
Acurastem, Inc.
$4,714,159
Attributed
$9,428,318
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,428,318 · 4
By mechanism
R44$9,203,383 · 3
R43$224,935 · 1
Top collaborators
- Wen-Hsuan Chang5 shared
- Hongyan Zhou4 shared
- Zhihua Feng2 shared
- Qing Liu-Michael1 shared
Most similar at Acurastem, Inc.
Same institution · by research overlap
- Wen-Hsuan Chang$2,212,802
- Zhihua Feng$2,782,758
- Hongyan Zhou$1,581,576
Others in their field
Other Emerging Leaders on “C9orf72”
- Joanne Wuu · University Of Miami School Of Medicine$7,140,362
- Evangelos Kiskinis · Northwestern University$4,559,814
- Tomohiro Nakamura · Scripps Research Institute, The$3,512,996
- Christopher James Donnelly · University Of Pittsburgh At Pittsburgh$3,326,428
- Adam Mark Staffaroni · University Of California, San Francisco$3,169,510
- Bin Wu · Johns Hopkins University$3,120,831
Research focus
C9orf72GeneticToxic EffectNew Therapeutic TargetNerve DegenerationAntisense OligonucleotidesMediatingEvaluationKnock-DownLeadAutophagocytosisSafetyPhosphotransferasesSmall MoleculeNeuronsGenesFrontotemporal DementiaAutopsyAmyotrophic Lateral SclerosisPhenotypeTissuesDna Sequence AlterationIn VivoNovel Therapeutic Intervention
Grant awards (12)
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1,402,110
R44 · FY2024 · AG · contact PI
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD$1,492,509
R44 · FY2023 · AG · contact PI
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1,480,550
R44 · FY2022 · NS · contact PI
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$76,492
R44 · FY2022 · NS · contact PI
Development of a PIKFYVE Antisense Oligonucleotide Treatment for FTD$40,846
R44 · FY2022 · NS · contact PI
Development of a PIKFYVE antisense oligonucleotide treatment for FTD$1,014,266
R44 · FY2021 · NS · contact PI
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$533,459
R44 · FY2021 · NS · contact PI
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1,148,751
R44 · FY2020 · NS · contact PI
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1,316,216
R44 · FY2019 · NS · contact PI
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$265,079
R44 · FY2019 · NS · contact PI
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$433,105
R44 · FY2018 · NS · contact PI
Preserving cellular aspects of aging in patient-specific models of ALS$224,935
R43 · FY2017 · AG · contact PI